Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Online ISSN 1827-1634
PREDIABETES AND THE METABOLIC SYNDROME
Sathyapalan T., Atkin S. L.
Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK
There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.